Physician profile
Danielle Chevonne Mcdevitt
NPI 1336567361
$925.33
in general payments reported to CMS, 2019-2025
16 companies · $60.62 in 2025
The $60.62 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $21.13 · 2021: $28.77 · 2022: $119 · 2023: $243 · 2024: $255 · 2025: $60.62.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $559.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $301.44 | 2022-2024 | Xifaxan, Trulance |
| Merz North America, INC. | $216.19 | 2024-2025 | |
| Abbvie INC. | $76.29 | 2021-2024 | |
| Lilly USA, LLC | $43.80 | 2019-2024 | Zepbound |
| Fidia Pharma USA INC. | $37.34 | 2022-2024 | Hymovis, Triluron, Hyalgan |
| Antares Pharma, INC. | $36.90 | 2019 | |
| Csl Behring | $35.25 | 2019 | |
| Galderma Laboratories, L.P. | $29.63 | 2023 | |
| Phadia US INC. | $27.54 | 2019 | |
| Revance Therapeutics, INC. | $27.51 | 2025 | Daxxify |
| Romark Laboratories, Lc | $21.13 | 2020 | |
| Grifols USA, LLC | $19.56 | 2019 | |
| Endo Pharmaceuticals INC. | $15.26 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.34 | 2019 | |
| Allergan, INC. | $11.87 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $11.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Mcdevitt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.